PERK-eIF2alpha-mediated translational inhibition of MCL-1 contributes to potential 2-deoxy-D-glucose and BAD mimetic combinatorial cancer therapy
Cellular Signalling · 2026
DOI: 10.1016/j.cellsig.2025.112333 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Signalling, 2026. Verfasst von Mengning Sun und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Animal Nutrition and Feeding, College of Animal Science and Technology, China Agricultural University, Beijing, China. Hauptthemen laut MEDLINE: Myeloid Cell Leukemia Sequence 1 Protein, Deoxyglucose, eIF-2 Kinase, Eukaryotic Initiation Factor-2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 66 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Glycolysis inhibitor 2-Deoxy-D-glucose (2DG) has been extensively studied as a potential therapeutic agent because tumors depend more on aerobic glycolysis than normal cells for their energy supply. However, the precise mechanism underlying 2DG's toxicity remains not so clear. In this study, we confirmed that 2DG induces apoptosis primarily by disrupting glycosylation rather than glycolysis. We observed that glucose depletion or 2DG treatment leads to a significant reduction of MCL-1 protein levels. Further analysis revealed that 2DG toxicity required MCL-1 degradation. Moreover, BAD was identified as the only BH3-only protein whose single knockout can block 2DG-induced apoptosis. The downregulation of MCL-1, combined with the dephosphorylation of BAD at Serine 155, contribute to the simultaneous inactivation of the anti-apoptotic functions of both MCL-1 and BCL-xL, which is sufficient to induce 2DG toxicity. Additionally, our experiments showed that Endoplasmic Reticulum (ER) stress induced PERK-eIF2α pathway mediated translational inhibition of MCL-1 contributes to 2DG toxicity. Based on these findings, the combined use of 2DG with BAD BH3 mimetic have proven effective against various types of cancer cells. In conclusion, this study provides a theoretical basis and rationale for the combined use of 2DG and BH3 mimetics as a promising therapeutic strategy for cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Animal Nutrition and Feeding, College of Animal Science and Technology, China Agricultural University, Beijing, China.
- State Key Laboratory of Animal Nutrition and Feeding, College of Animal Science and Technology, China Agricultural University, Beijing, China. Electronic address: dongna@cau.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Sun, M., Li, L., Fu, R., Yang, Q., Chen, W., Sun, Y., Gao, H., Gao, H., & Dong, N. (2026). PERK-eIF2alpha-mediated translational inhibition of MCL-1 contributes to potential 2-deoxy-D-glucose and BAD mimetic combinatorial cancer therapy. Cellular Signalling. https://doi.org/10.1016/j.cellsig.2025.112333
Vancouver
Sun M, Li L, Fu R, Yang Q, Chen W, Sun Y, et al. PERK-eIF2alpha-mediated translational inhibition of MCL-1 contributes to potential 2-deoxy-D-glucose and BAD mimetic combinatorial cancer therapy. Cellular Signalling. 2026. doi:10.1016/j.cellsig.2025.112333
BibTeX
@article{Sun2026,
author = {Sun, Mengning and Li, Li and Fu, Rongrong and Yang, Qinglan and Chen, Wenjuan and Sun, Yi and Gao, Hui and Gao, Hang and Dong, Na},
title = {PERK-eIF2alpha-mediated translational inhibition of MCL-1 contributes to potential 2-deoxy-D-glucose and BAD mimetic combinatorial cancer therapy},
journal = {Cellular Signalling},
year = {2026},
doi = {10.1016/j.cellsig.2025.112333}
}
EUVIMED